Publications by authors named "Devinder Gill"

Claim this Profile
R
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Melinda Burgess, Colm Keane, Josh Wd Tobin, Soi C Law, Alison Griffin, Devinder Gill

Acta Haematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Devinder Gill

Haematologica· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Richard Greil, Alessandra Tedeschi, Carol Moreno, Bertrand Anz, Loree Larratt, Devinder Gill

Ann Hematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients.
Yu-Chen Enya Chen, Melinda Burgess, Sally Mapp, Peter Mollee, Devinder Gill

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL.
Melinda Burgess, Yu Chen Enya Chen, Sally Mapp, Peter Mollee, Devinder Gill

Leuk Lymphoma· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cross-trial comparison of single-agent ibrutinib chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Alessandra Tedeschi, Richard Greil, Fatih Demirkan, Tadeusz Robak, Carol Moreno, Devinder Gill

Haematologica· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Diagnosis of fusion genes using targeted RNA sequencing.
Erin E Heyer, Ira W Deveson, Danson Wooi, Christina I Selinger, Ruth J Lyons, Devinder Gill

Nat Commun· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia.
Yu-Chen Enya Chen, Melinda Burgess, Sally Mapp, Peter Mollee, Devinder Gill

Leukemia· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
Courtney Tate, Melinda Burgess, Nigel A McMillan, Nicholas A Saunders, Catherine Cheung, Devinder Gill

Leuk Lymphoma· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of fusion genes using targeted RNA sequencing.
Erin E Heyer, Ira W Deveson, Danson Wooi, Christina I Selinger, Ruth J Lyons, Devinder Gill

Nat Commun· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Devinder Gill

Lancet Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, Neil E Kay, Nishitha M Reddy, Devinder Gill

Clin Lymphoma Myeloma Leuk· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Tadeusz Robak, Jan A Burger, Alessandra Tedeschi, Paul M Barr, Carolyn Owen, Devinder S Gill

Am J Hematol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia.
Kyaw Ze Ya Maung, Paul J Leo, Mahmoud Bassal, Debora A Casolari, James X Gray, Devinder Gill

Blood Cancer J· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Kenneth F Bradstock, Emma Link, Juliana Di Iulio, Jeff Szer, Paula Marlton, Devinder Gill

J Clin Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Devinder Gill

Haematologica· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Emma Taylor, Mark Jones, Matthew J Hourigan, David W Johnson, Devinder S Gill

Nephrol Dial Transplant· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Colm Keane, Frank Vari, Mark Hertzberg, Kim-Anh Lê Cao, Michael R Green, Devinder Gill

Lancet Haematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Stephen P Mulligan, Karin Karlsson, Mats Strömberg, Viggo Jønsson, Devinder Gill

Leuk Lymphoma· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C Byrd, Jennifer R Brown, Susan O'Brien, Jacqueline C Barrientos, Neil E Kay, Devinder Gill

N Engl J Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry.
Rebecca L C Adams, Catherine Cheung, Raymond Banh, Russell Saal, Donna Cross, Devinder Gill

Cytometry B Clin Cytom· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD62L as a therapeutic target in chronic lymphocytic leukemia.
Melinda Burgess, Devinder Gill, Richa Singhania, Catherine Cheung, Lynne Chambers

Clin Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Colm Keane, Devinder Gill, Frank Vari, Donna Cross, Lynn Griffiths

Am J Hematol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Kimberley Jones, Frank Vari, Colm Keane, Pauline Crooks, Jamie P Nourse, Devinder Gill

Clin Cancer Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.
Howard Mutsando, Magid Fahim, Devinder S Gill, Carmel M Hawley, David W Johnson

Am J Blood Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis